INTRODUCTION
Carotenoids are important cellular components in animals and humans. Experimental studies indicate that they enhance the immune system 1 , inhibit mutagenesis 2 , reduce chemically induced neoplasia 3 , and protect tissues from ultraviolet UV light-related damage 4 . Together with β-carotene, lutein, and lycopene, the potential antioxidant function of astaxanthin has been investigated 5 . Astaxanthin occurs naturally in plants and algae, and is commercially available as a food supplement from Haematococcus algae 6 . Little is known regarding the bioavailability of astaxanthin in humans, especially for Japanese middleaged and senior subjects. Recently, we conducted a randomized, double-blind human trial to assess the effi cacy of 12-week astaxanthin supplementation 6 or 12 mg/day 7 .
We confi rmed that erythrocyte astaxanthin concentrations after oral intake of 6 or 12 mg/day for 12-weeks were signifi cantly higher than erythrocyte astaxanthin concentrations observed before astaxanthin supplementation. Supplementation of astaxanthin for 12 weeks 12 mg/day also resulted in a signifi cant decrease in erythrocyte phospholipid hydroperoxide PLOOH concentrations in senior subjects 7 .
In this study, erythrocyte carotenoids and PLOOH con-centrations were determined by high-performance liquid chromatography HPLC in Japanese middle-aged and senior individuals, after 4-and 12-weeks intake of 1 or 3 mg/day astaxanthin. Therefore, astaxanthin supplementation was lower in this study than in our previous study 7 .
The principal objective was to investigate whether 1 or 3 mg of astaxanthin taken daily in Japanese subjects affects erythrocyte astaxanthin and PLOOH concentrations.
EXPERIMENTAL PROCEDURES

Subjects and supplementation trial
The present study was conducted according to the guidelines laid down in the Declaration of Helsinki, and all procedures involving human subjects were approved by the ethics committee of TES Holdings Co. Ltd. Tokyo; ethics no. YH03-2010-04 . A total of 30 Japanese middleaged and senior subjects between 40 and 69 years of age mean SD : 50.6 7.4 years for 0 mg placebo group 10 men , 51. 4 Throughout the study period, the subjects were instructed to maintain their usual lifestyle avoid excessive eating and drinking, intense exercise, and lack of sleep . Adverse effects were assessed by interviews and self-reports, and compliance was checked by self-reports and returned capsule counts. Dietary intake, alcohol consumption, and physical activity pedometer count during the 3 days before each blood collection 0-, 4-, and 12-week were also assessed by self-reports.
Determination of erythrocyte astaxanthin and other
carotenoids Before, during, and after the supplementation period 0-, 4-and 12-week , blood was drawn from the subjects after an overnight fast, using heparin as an anticoagulant. The blood was subjected to centrifugation at 1000 g for 10 min at 4 . After the plasma and buffy coat were removed, erythrocytes were washed 3 times with phosphate-buffered saline pH 7.4 to prepare packed cells. For the determination of erythrocyte carotenoids including astaxanthin , packed cells 2.5 mL were diluted with 2.5 mL of water and then mixed with 5 mL of 80 mM -ethanolic pyrogallol, 1.0 mL of 1.8 M -aqueous potassium hydroxide KOH , and 40 μL of 1 μM -ethanolic echinenone internal standard . After addition of 1.25 mL of 0.1 M aqueous sodium dodecyl sulfate, the sample was mixed with 15 mL of hexane and dichloromethane 5:1 to extract erythrocyte carotenoids. The extract was purified using a Sep-Pak silica cartridge Waters, Milford, MA, USA , and then subjected to HPLCtandem mass spectrometry MS/MS for the determination of astaxanthin concentration. Because astaxanthin has high polarity and tends to overlap with other erythrocytic compounds, HPLC-MS/MS was employed to for the structure-specifi c detection of astaxanthin.
For the determination of astaxanthin, a stock solution was prepared by dissolving an astaxanthin standard in tetrahydrofuran at a concentration of 1 to 5 mM. The concentration of astaxanthin was checked spectrophotometrically using its extinction coefficient 8, 9 . The astaxanthin standard and erythrocyte extracts were analyzed using HPLC-MS/MS equipment, which consisted of a liquid chro- The fl ow rate was adjusted to 1 mL/min, and the column temperature was maintained at 25 . Astaxanthin was determined in the post-column by MS/MS with multiple reaction monitoring MRM for the transition of the parent ion to the product ion 7 .
For the determination of other carotenoids, standard carotenoid solutions were prepared in a similar way, and erythrocyte extracts were analyzed by HPLC coupled with UV diode array detection DAD and APCI MS, as previously described 7, 8 .
Determination of erythrocyte phospholipid hydroperoxides
For the determination of erythrocyte PLOOH concentrations, total lipids were extracted from packed cells with a mixture of 2-propanol and chloroform containing EDTA2Na. Using erythrocyte total lipids, PLOOH levels phosphatidylcholine hydroperoxide PCOOH and phosphatidylethanolamine hydroperoxide PEOOH were measured by HPLC coupled with chemiluminescence CL detection 10 12 .
The column was a 4.6 250 mm, 5-μm Finepak SIL NH2-5 column Japan Spectroscopic Co., Tokyo, Japan , the eluent used was 2-propanol:methanol:water 135:45:20 , and the fl ow rate was 1 mL/min. Post-column CL detection was carried out using a CLD-100 detector Tohoku Electronic Industries Co., Sendai, Japan . A mixture of luminol and cytochrome C in 50 mM borate buffer pH 10.0 was used as a hydroperoxide-specifi c post-column CL reagent. Calibration was carried out using PCOOH and PEOOH standards.
Statistical analysis
Data were analyzed using IBM SPSS Statistics Ver. 19 IBM Inc., NY, USA . Two-way mixed model analysis of variance ANOVA was used to test astaxanthin dose groups and treatment period weeks effects on erythrocyte carotenoid and PLOOH concentrations. In cases where interactions were identified, individual differences between means in each group were determined with the Bonferroni post-hoc test.
RESULTS AND DISCUSSION
When the astaxanthin standard was analyzed by MS/MS with fl ow injection, it displayed an intense molecular ion at m/z 597 M H . Product ion scanning was conducted for the ion, and astaxanthin-specific fragment ions e.g., m/z 147 were identifi ed. These ions, such as m/z 597 and 147, allowed the determination of erythrocyte astaxanthin concentrations using HPLC-MS/MS with MRM 7 Fig. 1A . In a typical MRM chromatogram of erythrocyte extract taken after supplementation, astaxanthin was clearly detected Fig. 1B . As shown in Table 1 , signifi cant interactions p 0.001 were observed between astaxanthin supplementation and erythrocyte astaxanthin levels in Japanese middleaged and senior subjects. Bonferroni post-hoc tests showed
Fig. 1 Typical multiple reaction monitoring (MRM)
chromatograms of standard astaxanthin (1 pmol, A) and human erythrocyte astaxanthin (10 μL of erythrocyte extract prepared from astaxanthinsupplemented subject 3 mg/day for 12 weeks , B). that a 3-mg dosage of astaxanthin for 4 and 12 weeks significantly increased erythrocyte astaxanthin levels p 0.05 . When standard carotenoids were subjected to HPLC-DAD by using a C30 column, they were well separated and eluted as follows: lutein, β-cryptoxanthin, zeaxanthin, echinenone internal standard , α-carotene, β-carotene, and lycopene. DAD limits for carotenoids were in the range of 0.1 to 0.25 pmol at a signal-to-noise ratio of 3. With regards to erythrocyte carotenoids in Japanese middleaged and senior subjects, lutein, β-cryptoxanthin, zeaxanthin, and β-carotene were detected, with lutein being the most predominant Table 1 . Astaxanthin supplementation did not affect the concentrations of other carotenoids.
PCOOH and PEOOH were detected as the predominant PLOOH forms in erythrocytes. Astaxanthin supplementation 1 or 3 mg/day did not affect erythrocyte PLOOH concentrations sum of PCOOH and PEOOH Table 2 . This may be due to the astaxanthin intake being lower in the current study than in our previous study 7 . The present results suggest that supplementation of astaxanthin 3 mg/ day increases erythrocyte astaxanthin concentrations, but this dosage is not enough to prevent membrane phospholipid hydroperoxidation in erythrocytes. There are several reports regarding the bioavailability of astaxanthin in humans, but few focus on Japanese subjects 13 15 . Carotenoids are the most widespread group of hydrophobic pigments found in food. They may play a crucial role as electron-transport agents to protect organs, tissues, and cells from the damaging actions of reactive oxygen species and lipid peroxides, if they are present in suffi cient amounts.
In conclusion, it was confi rmed that erythrocyte astaxanthin concentrations were signifi cantly increased in Japanese middle-aged and senior individuals supplemented for 4 and 12 weeks with 3 mg/day of astaxanthin. Signifi cantly, this study suggests that even a low dose of astaxanthin consumption 3 mg/day contributes to an increase in erythrocyte astaxanthin concentrations in Japanese subjects. 
